United States · 
What does Versant Ventures invest in?
Versant Ventures invests most often at Series B and Series A (55% of the rounds on record), in sectors such as Connected Health, E-health and Healthier Living.
Versant Ventures highlights
- 01
7 cheques in the last 12 months
- 02
Mostly Series B and Series A: 55% of its rounds
- 03
Sole investor in 24 rounds, median $20M
- 04
29 exits from the portfolio
What they do
Versant partners with exceptional entrepreneurs to build and fund breakthrough biotechnology companies around the globe.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- $100K – $5.0M as they say
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- Connected HealthE-healthHealthier Living
- Based in
- San Francisco, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first256 appearances
- 2026
4 rounds
- Oct
- Sept
- Mar
- Jan
- 2025
8 rounds
- Dec
- Nov
- Nov
- Sept
- Sept
- Apr
- Jan
- Jan
- 2024
12 rounds
- Dec
- Dec
- Sept
- Aug
- Jul
- Jun
- Jun
- May
- Apr
- Mar
- Feb
- Jan
- 2023
6 rounds
- Nov
- Sept
- Jul
- Apr
- Feb
- Jan
- 2022
9 rounds
- Dec
- Nov
- Nov
- Oct
- Oct
- Sept
- Aug
- May
- Apr
- 2021
9 rounds
- Dec
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration23 named
AMAlex MaywegManaging Director of the Ultimate General PartneriFiling they signed
AVAlexander Volker MaywegManaging Director, Versant Ventures (Switzerland) GmbhiForm ADV
BNBarbara N. LubashManaging Director of the General Partner of the IssuseriFiling they signed
BJBradley J. BolzonManager of the General Partner of the General Partner of ParalleliFiling they signed
BGBrian G. AtwoodManaging Member, Versant Venture Management, LLCiForm ADV
CDCamille D. SamuelsManaging DirectoriFiling they signed
CDCarlo Dante RizzutoManaging Director of the Ultimate General PartneriFiling they signed
CMCharles M. WardenManaging Member, Versant Venture Management, LLCiForm ADV
COClare OzawaManaging Director of the Ultimate General PartneriFiling they signed
DBDonald B. MilderManaging Member, Versant Venture Management, LLCiForm ADV
JCJerel Clayton DavisDirector of the General Partner of Voyageurs and Manager of the General Partner of the General Partner of ParalleliFiling they signed
KLKirk L. NielsenManager of the General Partner of the General Partner of ParalleliFiling they signed
MMMarkus Michael EnzelbergerDirector of Versant Ventures (Switzerland) GmbhiForm ADV
MBMax Benjamin EisenbergGeneral Counsel, Versant Venture Management, LLCiForm ADV
RBRebecca B. RobertsonManaging DirectoriFiling they signed
RDRichard D. Van DorenCFO, Versant Venture Management, LLCiForm ADV
RLRobin L. PraegerDirector and President of the General Partner of Voyageurs and Manager of the General Partner of the General Partner of ParalleliFiling they signed
RARoss A. JaffeManaging Member, Versant Venture Management, LLCiForm ADV
SCSam ColellaManageriFiling they signed
SDSamuel D. ColellaManaging Director of the General Partner of the IsueriFiling they signed
TFThomas F. WoiwodeManager of the General Partner of the General Partner of ParalleliFiling they signed
TLTom L. WoiwodeManaging DirectoriFiling they signed
WJWilliam J. LinkManaging Member, Versant Venture Management, LLCiForm ADV
We also hold 61 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$3.9Bgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Versant Venture Management, LLC
- SEC number
- CRD 161130
What they claim to have backed
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed29 in all
Novira TherapeuticsBought by Johnson & JohnsonUndisclosedNov 2015
Skylight Healthcare SystemsBought by GetWellNetwork, Inc.UndisclosedSept 2015
CardiAQ Valve TechnologiesBought by Edwards Lifesciences$350MJul 2015
Kythera BiopharmaceuticalsBought by Allergan$2.1BJun 2015
WaveTec VisionBought by AlconUndisclosedSept 2014
Trius TherapeuticsListedUndisclosedJul 2013
Trius TherapeuticsBought by Cubist Pharmaceuticals$707MJul 2013
Five Prime TherapeuticsListedUndisclosedJul 2013
OkairosBought by GlaxoSmithKline$325MMay 2013
Cameron HealthBought by Boston ScientificUndisclosedJun 2012
Clovis OncologyListed$130MNov 2011
Calypso MedicalBought by Varian Medical SystemsUndisclosedSept 2011
Amira PharmaceuticalsBought by Bristol-Myers Squibb$325MJul 2011
Synosia TherapeuticsBought by Biotie Therapies$122MJan 2011
LensX LasersBought by AlconUndisclosedJul 2010
ConcuityBought by The Advisory Board CompanyUndisclosedMar 2010
AcclarentBought by Johnson & Johnson$785MDec 2009
ConfirmaBought by Merge HealthcareUndisclosedAug 2009
NeoGuide SystemsBought by Intuitive SurgicalUndisclosedJun 2009
The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.